COVID-19-imposed health care restrictions had no negative effects on status of DME
October 03, 2022
DME showed small significant improvement in study cohort.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Retina
AAO LIVE: Researchers target risk factors for development of rhegmatogenous retinal detachments
October 03, 2022
In a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, William Kearney and Dan Gong, MD, discussed how patients with a unilateral retinal detachment frequently ask about the risk of developing an RRD in their fellow eye.
Pooled Phase 3 data reports safety, efficacy, reduced treatment burden with faricimab compared with aflibercept for the treatment of nAMD
October 02, 2022
The AVONELLE-X long-term extension study will continue to evaluate the efficacy, durability, and safety of faricimab in patients with neovascular AMD.
AAO LIVE: Study finds retinal detachment rates unaffected by early treatment with intravitreal antivirus or vitrectomy in patients with acute retinal necrosis
October 02, 2022
In a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, Ines Lains, MD, PhD, detailed how adjunct treatment with intravitreal antivirals or early pars plana vitrectomy did not improve the rates of retinal detachment in patients diagnosed with acute retinal necrosis.
Center-involved DME resolves faster with faricimab than aflibercept
October 02, 2022
The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.
AAO: Janssen announces late-breaking data from a pair of gene therapy programs
October 02, 2022
In an announcement at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago, the company noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.
Discussing how fluid dynamic affect visual acuity in wet macular degeneration
October 01, 2022
At the 2022 American Academy of Ophthalmology meeting, Justis Ehlers, MD, presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"
Apellis announces 24-ponth Phase 3 study of pegcetacoplan for GA
October 01, 2022
Data were presented during an oral presentation at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago.
Faricimab: YOSEMITE, RHINE treat-and-extend data illustrate favorable personalized treatment dynamics for the treatment of DME
September 30, 2022
Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."
EP. 2: EyeCon 2022: Location, location, location and bring the family
September 28, 2022
The destination of Marco Island, Florida not only serves as an excellent backdrop for this year's Ophthalmology Times® EyeCon 2022 but also provides a unique opportunity for family members to see their ophthalmic loved ones in a professional light.